| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| HIV Infections | |||||
| Fatigue | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Acquired Immunodeficiency Syndrome | |||||
| Infection | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| Immunologic Deficiency Syndromes | |||||
| Lentivirus Infections | |||||
| Retroviridae Infections | |||||
| RNA Virus Infections | |||||
| Sexually Transmitted Diseases | |||||
| Sexually Transmitted Diseases, Viral | |||||
| Signs and Symptoms | |||||
| Slow Virus Diseases | |||||
| Virus Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Modafinil | |||||
| 5 | More general drug interventions related to this trial | ||||
| Central Nervous System Agents | |||||
| Central Nervous System Stimulants | |||||
| Neuroprotective Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Protective Agents | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| National Institute of Mental Health (NIMH) | |||||
|
